Articles & patient guides

Charitable foundations covering rare-disease drug costs

A short list of US, EU and MENA foundations that fund rare-disease drug procurement; eligibility, application windows and what they will not pay for.

↑ Back to top

Comparing specialty pharmacy quotes, what to ask for

A quote without lot-level pricing, cold-chain handling, duties, broker fees and a written refund clause is not a real quote; it is a starting position.

Crypto vs wire vs check for cross-border medical purchases

US specialty pharmacies almost universally require fiat wire. Crypto is rarely accepted, almost never for cold-chain biologics, and complicates AML and tax records.

Currency hedging on large medical purchases

For purchases over USD 100,000 between quote and wire, a forward contract or a same-day spot-rate lock can save more than it costs.

Family-pooled funding models for million-dollar gene therapies

Pooled financing structures for one-time gene therapies above USD 1M: trust accounts, family LLCs, and the tax treatment of intra-family gifts versus loans.

How patients abroad pay for US specialty drugs

Most international cash-pay patients use a wire transfer to a US specialty pharmacy after a firm quote, not a card, not crypto, not escrow.

International wire transfer best practices for medical purchases

Bank-to-bank SWIFT with the correct intermediary and correspondent fields prevents a five-day delay that can sit between a quote and a CAR-T infusion.

Manufacturer patient assistance programs explained

PAPs vary by manufacturer, drug, indication and country. Most large pharma run a foundation arm plus a direct PAP; very few extend to non-US residents.

Tax deductibility of medical purchases abroad, country-specific

How the US, UK, UAE, India, KSA, Egypt and Pakistan treat the deductibility of legally imported personal medicines on individual returns.

Why cash-pay is often cheaper than insurance for specialty drugs

When a specialty drug has a high deductible, a coinsurance ladder, and a US WAC several multiples over the international price, cash-pay abroad can be the lower number.

CDSCO Form 12A vs Form 10 vs Form 11, India

Form 12A is the personal-import licence for a named patient; Form 10 and Form 11 are commercial-import licences. Mixing them up is the most common India access mistake.

↑ Back to top

Egypt EDA pre-market authorization paths

Egypt's EDA recognises pre-market and named-patient routes for unregistered drugs; rare-disease cases route through a dedicated committee with hospital sponsorship.

EMA compassionate use vs hospital exemption

Article 83 compassionate use is cohort-based, hospital exemption is per-batch ATMP. Patients and physicians regularly conflate the two; the legal bases differ.

FDA Right-to-Try Act, what it does and does not do

Right-to-Try lets terminal US patients ask a manufacturer for an unapproved drug; it does not bypass the manufacturer's right to decline and does not apply abroad.

Lebanon thalassemia and cancer drug access pathways

Lebanon's MoPH operates a dedicated thalassemia and oncology programme for unregistered drugs; private-sector named-patient routes coexist with public supply.

MHRA Early Access to Medicines Scheme, UK

EAMS is a two-step, voluntary, manufacturer-led scheme. PIM and scientific-opinion designations do not equal NHS funding; that is a separate negotiation.

Pakistan DRAP one-stop import portal walkthrough

DRAP's online portal accepts personal-import applications with prescription, passport, and a treating-physician declaration; processing now averages 7-14 days.

PMDA off-label and unapproved drug access, Japan

Japan permits personal import via the Yakkan Shoumei pathway and physician-led off-label use within institutional protocols; bulk import is restricted.

SFDA Special Access Programme, Saudi Arabia

Saudi Arabia's SFDA permits hospital-led import of unregistered drugs for named patients via a structured Special Access pathway and an MoH committee review.

UAE compassionate use vs named patient program

MOHAP, DoH Abu Dhabi and DHA Dubai each operate distinct pathways; the choice depends on emirate of treatment, drug-registration status and clinical urgency.

Antibody-drug conjugates and country availability

ADC approvals trail US registration by 2-4 years in most emerging markets; named-patient import is the only realistic route for the latest ADCs outside the US, EU and Japan.

↑ Back to top

Biosimilars, when and where they help

EU and India lead in biosimilar uptake; the US trails. Biosimilars deliver 30-60 percent savings versus originators where they are available and clinically suitable.

Bispecific antibodies in emerging-market access

Bispecifics for hematology and solid tumors carry REMS, cytokine-release-syndrome monitoring, and step-up dosing; named-patient import works only with a hospital partner.

BTK inhibitors comparative access globally

Ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib have very different country-by-country registration. The right molecule depends on what is locally available.

CAR-T therapy international logistics

Autologous CAR-T involves leukapheresis, cryogenic transport in dry-shipper dewars, a manufacturing slot, and a return shipment; almost no country imports it as a named-patient drug.

Cold-chain biologics, what can and cannot be shipped

2-8C biologics travel well with validated shippers; -20C and -70C agents need active or dry-ice protocols; some live-cell products are essentially non-shippable.

Gene therapy at USD 2M plus, access logistics globally

One-shot gene therapies introduce eligibility windows, single-dose pricing, manufacturer-direct supply, and country-level coverage gates that are not negotiable.

GLP-1 receptor agonists international supply chain

GLP-1 cross-border demand peaked in 2024-2025; pen and prefilled-syringe shortages persist. Most national regulators have tightened personal-import for GLP-1s.

Oral oncology vs IV oncology shipping

Oral oncolytics are typically room-temperature, blister-packed, and air-shipped with minimal customs friction; IV oncology requires cold-chain plus hospital-pharmacy receipt.

Orphan drugs in non-US countries

Orphan designation in the US, EU and Japan opens incentives for manufacturers; for patients abroad, it usually means a small commercial footprint and named-patient supply.

30-day delivery timelines, realistic expectations by country

UAE 7-14 days; KSA 10-21 days; India 14-30 days; Pakistan 21-45 days; EU 14-30 days. Pre-cleared regulatory routes shave 30-50 percent off these windows.

↑ Back to top

Caregiver guide for million-dollar treatment imports

For caregivers managing a one-time gene therapy or a year of CAR-T follow-on care: document custody, financial controls, decision logs, and the family conversation calendar.

Choosing between US WAC, EU price, India price

The same molecule can carry a US WAC of USD 18,000 a month, an EU public price of USD 6,500, and an India price of USD 1,200. Each carries different supply, registration and shipping trade-offs.

First-time international drug buyer checklist

A nine-item checklist covering prescription, indication, country eligibility, quote, refund clause, cold-chain, customs, broker, and treating-physician receipt.

Patient passport documents required for cross-border purchases

Most national regulators require a passport copy, prescription, treating-physician letter, and an import declaration; a few add an embassy attestation or notarisation.

Translating prescriptions across regulatory bodies

A prescription accepted in the US is not automatically accepted in UAE, KSA, India or the EU; translation, attestation, and re-issue by a locally licensed physician are usually required.

Travel-for-treatment vs ship-the-drug

Cell therapies and complex infusions usually require travel; small molecules, oral agents, and many biologics can be shipped to the patient's treating physician.

When NOT to source internationally, safety and scams

Unlicensed pharmacies, prices that look too good, requests for crypto or escrow, missing DSCSA paperwork, and refusal to use a treating-physician hand-off are red flags.

When to involve your home-country oncologist in international access

Home-country oncologist sign-off is required by most named-patient pathways and almost always required to administer the drug once it arrives.

Why specialty drugs cost 80 percent less abroad

International prices reflect reference pricing, public-system negotiations, lower R and D recoupment, and in some cases compulsory licensing; not lower quality or counterfeits.

2026 vs 2027, drug access landscape predictions

What is changing in 2027: more orphan-drug entries, broader biosimilar interchangeability, India CDSCO portal upgrades, and EU joint clinical assessment going live.

↑ Back to top

Buying brand vs biosimilar internationally

Originator carries the longest safety record; biosimilars cut cost meaningfully where regulators have accepted interchangeability. The decision is jurisdiction-specific.

Crowdfunding gene therapy, when it works

Crowdfunding closes a fraction of one-time gene-therapy budgets; success correlates with a clear medical story, an early local-press anchor, and a credible custody plan for the funds.

Generic vs brand-name from approved foreign manufacturers

An EMA-approved Indian generic and an FDA-approved US brand can be clinically equivalent; the procurement, customs and provenance paperwork is what differs.

Importing through a clinic vs direct patient import

Clinic-led import sits inside a hospital pharmacy receipt; direct-patient is shorter but exposes the patient to customs and administration risks.

Outsourcing vs DIY cross-border procurement

DIY can work for shelf-stable oral drugs in liberal regulators; cold-chain biologics, REMS drugs and high-value oncology essentially require an operator with documented chain-of-custody.

Reserve Meds vs everyone.org vs IndianPharmaNetwork

Three operators, three models: a US-sourced cash-pay luxury concierge, a European subscription marketplace, and an India-sourced direct generic supplier.

Specialty pharmacy vs direct manufacturer vs hospital procurement

Three procurement channels with very different documentation, pricing, lead time, and refund profiles. The right choice depends on the drug, urgency and destination.

When clinical trials are a better option than international access

Drug-cost-zero trial participation can beat any procurement pathway, when there is a trial, when the patient qualifies, and when travel and follow-up are practical.

When to use a named patient program vs compassionate use

Named-patient is patient-paid and patient-driven; compassionate use is manufacturer-supplied at no cost. Eligibility overlaps but is not identical.

Articles & guides

Financial, payment and insurance

Regulatory and pathways

Drug-class deep dives

Patient journey and clinical

Comparison and decision

All articles A-Z

Related on Reserve Meds